G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

NAT2

N-Acetyltransferase 2

CHR 8
8p22

Overview

The NAT2 gene is one of the founding discoveries of human pharmacogenetics. During Phase II liver conjugation, NAT2 attaches an acetyl group to amine- and hydrazine-containing molecules—rendering them water-soluble for renal or biliary excretion.

Roughly half of Europeans and North Americans carry two reduced-function haplotypes (slow acetylators), whereas East Asian populations are predominantly rapid acetylators—directly influencing tolerability of tuberculosis drugs, sulfonamides, and environmental arylamines.

📍 Position
8p22 (Chromosome 8)
🏷️ Category
Detoxification & Phase II Liver
🧪 Function
Phase II Acetylation Enzyme
📊 Influence
Slow vs. rapid drug acetylation

Function of NAT2

NAT2 works in the liver and intestinal mucosa alongside glutathione transferases (GSTP1) and glucuronidation (UGT1A1). When acetylation slows down, alternative reactive metabolites can accumulate if co-exposures run high.

Key Aspects:

🐢 Slow Acetylators (*5, *6, *7 pairs)

Two reduced-activity alleles prolong clearance of isoniazid, hydralazine, procainamide, and sulfamethoxazole, elevating drug-toxicity risk at standard doses.

🔥 Environmental Arylamines

Slow acetylators show lower clearance of aromatic amines from cigarette smoke and high-temperature charred meats, making smoking cessation and gentle cooking especially protective.

💡 Clinical Context: Before long-term isoniazid therapy, physicians often supplement vitamin B6 (pyridoxine) to prevent peripheral neuropathy, particularly in slow acetylators.

🧬 Genetic Variants (SNPs)

Testing NAT2 haplotypes combines key SNPs such as *5 (rs1801280) and *6 (rs1799930) to infer acetylator speed:

rs1801280
8:18400344
Rapid (*4)

T
/
Slow (*5)

C
NAT2*5 (Ile114Thr)
Tag SNP for the most common European slow-acetylator haplotype; lowers catalytic NAT2 protein stability sharply.
*5 allele frequency:
~45% (Europe)
rs1799930
8:18400593
Rapid (*4)

G
/
Slow (*6)

A
NAT2*6 (Arg197Gln)
Causes misfolded, poorly active NAT2 enzyme; compound carriers (*5/*6) classify clearly as slow acetylators.
*6 allele frequency:
~28% (Europe)

Practical Significance

✅ Strategies & Guidance

  • Gentle Cooking Methods: Prefer steaming, braising, or marinades (rosemary/garlic) over heavily charred grilling to limit heterocyclic amines.
  • Avoid Tobacco Smoke: Zero exposure spares slow NAT2 pathways from aromatic amine overload.
  • Support General Liver Co-Factors: Cruciferous vegetables (sulforaphane) and adequate B vitamins bolster complementary Phase II detoxification.

⚠️ Clinical Notes & Risks

  • Isoniazid & Sulfonamide Toxicity: Higher odds of liver enzyme elevation or rash on weight-standard dosing.
  • Drug-Induced Lupus Risk: Reported more frequently in slow acetylators treated long-term with hydralazine or procainamide.
  • Haplotype Complexity: Reliable phenotyping requires assessing *5, *6, *7, and *14 together rather than one SNP alone.
🩺 Medical Disclaimer: Genetic test results for NAT2 (N-Acetyltransferase 2) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #612182 (N-Acetyltransferase 2)
  • dbSNP: rs1801280 (*5), rs1799930 (*6)
  • PharmGKB: NAT2 Acetylation Status & Drug Toxicity Annotations
  • PubMed: Hein DW – Molecular genetics and function of NAT1 and NAT2

Last Update: November 2026

Related Genes in Detoxification